Aadi Bioscience (AADI) Announces Management Changes

Go back to Aadi Bioscience (AADI) Announces Management Changes

Aadi Bioscience Announces Planned Leadership Transition

November 8, 2022 4:00 PM EST

LOS ANGELES, Nov. 8, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Neil Desai, Founder, President and CEO to Executive Chairman and Brendan Delaney, Chief Operating Officer, to President and CEO, effective as of January 1, 2023. 

"I have had the opportunity to work with Brendan since he joined Aadi as Chief Operating Officer in September 2021. Since that time his... More